AB0214 Adiponectin Determination in Rheumatoid Arthritis Patients Complicated by Osteoporosis

BackgroundBone mineral density and proteins/peptides determination in blood and urine as markers of bone resorption and formation are currently used to diagnose osteoporosis (OP) and metabolic bone diseases. However, these methods have some disadvantages for bone turnover evaluation. Recent evidence...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2016-06, Vol.75 (Suppl 2), p.970-971
Hauptverfasser: Seewordova, L., Polyakova, J., Zavodovsky, B., Akhverdyan, Y., Kuznetsova, M., Zborovsky, I.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundBone mineral density and proteins/peptides determination in blood and urine as markers of bone resorption and formation are currently used to diagnose osteoporosis (OP) and metabolic bone diseases. However, these methods have some disadvantages for bone turnover evaluation. Recent evidence suggests that in RA changes in the secretion of hormones of white adipose tissue can be revealed [1,2]. One of them is Adiponectin possessing anti-inflammatory, anti-diabetic and anti-atherogenic properties. Changes in Adiponectin levels may reflect influence of immune inflammation on bone turnover.ObjectivesTo study the clinical and diagnostic value of serum Adiponectin determination in RA patients complicated by OP.MethodsWe examined 88 women with documented diagnosis of RA and mean disease duration of 6.56±0.88 years. We used EULAR/ARA 2010 criteria to diagnose the patients. Female patients with II degree of disease activity (DAS28), Steinbrocker stage II (erosive), rheumatoid factor- and anti-cyclic-citrullinated peptide antibody-positive were prevalent. We excluded patients who had surgery or developed an infection within the last 8 weeks, pregnant and breast-feeding women, those with severe heart, liver or kidney disease, immune deficiency, leukopenia or chronic infection.A control group of 45 healthy females aged of 25 and 59 years were included in the study. There were no reported findings of joint pain and RA symptoms in the group. The groups were adjusted for age (p>0.05) and showed no statistically significant differences.We measured serum Adiponectin levels (μg/ml) using Human Adiponectin ELISA commercial test systems (BioVendor, Czech Republic, cat No. RD195023100). We used spectrophotometer with wavelength of 450 nm to detect the test results (“Multiskan” immunoenzyme analyzer, Finland). We plotted a curve using computer software. We diagnosed OP using dual-energy X-ray absorptiometry with LUNAR DPX PRO (GE, USA).ResultsSerum adiponectin levels in the control group were 12.5±0.9 μg/ml (M±m). Adiponectin levels in healthy subjects measured as M ±2d, ranged between 0.44 and 24.56 μg/ml. Patients with OP and RA had significantly higher levels of serum Adiponectin (p
ISSN:0003-4967
1468-2060
DOI:10.1136/annrheumdis-2016-eular.1076